Nektar at buy from Merrill

Merrill Lynch analyst Hari Sambasivam rated Nektar Therapeutics at buy and increased his 12-month price objective to $28 from $23 after including revenues from proprietary products. Merrill believes these products, inhaled amphotericin B and inhaled amikacin, could eventually compete in premium-priced niches with sizable revenue potential. Shares of the San Carlos, Calif., biopharmaceutical company were down $0.90 or 4.04%, at $21.40 on volume of 2,204,974 shares versus the three-month running average of 1,508,540 shares. (Nasdaq: NKTR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.